Smilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones and reverses the decrease of neuronal... Pre-clinical work with smilagenin showed it to be neuroprotective against betya-amyloid and glutamate damage which contributes to Alzheimer's disease and reverses the changes in the area of the brain involved in Parkinson’s disease.
- Mechanism
- Curator reviewed
Smilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones and reverses the decrease of neuronal growth factors and dopamine receptors in the brain.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, parkinson's disease and other neurodegenerative diseases.Curator reviewed
- Formula / weight
- C27H44O3 · 416.6365 g/mol (avg)
- Also known as
- (25R)-5beta-Spirostan-3beta-ol · Isosarsapogenin
- Code names
- PYM-50028
Resolves to
GMBQZIIUCVWOCD-UQHLGXRBSA-NSMILES[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2What you can answer from here — as of July 03, 2026
Which drugs share a target with Smilagenin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account